260 related articles for article (PubMed ID: 8889461)
1. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
[TBL] [Abstract][Full Text] [Related]
2. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
3. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
[TBL] [Abstract][Full Text] [Related]
4. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
[TBL] [Abstract][Full Text] [Related]
5. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
[TBL] [Abstract][Full Text] [Related]
6. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
7. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
[TBL] [Abstract][Full Text] [Related]
8. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
9. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans.
Londong W
Aliment Pharmacol Ther; 1994; 8 Suppl 1():39-46. PubMed ID: 8180293
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial.
Avgerinos A; Sgouros S; Viazis N; Vlachogiannakos J; Papaxoinis K; Bergele C; Sklavos P; Raptis SA
Scand J Gastroenterol; 2005 May; 40(5):515-22. PubMed ID: 16036503
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
Wo JM; Koopman J; Harrell SP; Parker K; Winstead W; Lentsch E
Am J Gastroenterol; 2006 Sep; 101(9):1972-8; quiz 2169. PubMed ID: 16968502
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration.
Ehrlich A; Lücker PW; Wiedemann A; Sander P; Huber R; Mascher H
Methods Find Exp Clin Pharmacol; 1999; 21(1):47-51. PubMed ID: 10222447
[TBL] [Abstract][Full Text] [Related]
14. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
15. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
[TBL] [Abstract][Full Text] [Related]
16. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
18. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.
Tutuian R; Katz PO; Bochenek W; Castell DO
Aliment Pharmacol Ther; 2002 Apr; 16(4):829-36. PubMed ID: 11929403
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding.
Brunner G; Luna P; Hartmann M; Wurst W
Yale J Biol Med; 1996; 69(3):225-31. PubMed ID: 9165691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
